Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Business Wire May 26, 2022

Xencor Reports First Quarter 2022 Financial Results

Business Wire May 5, 2022

Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022

Business Wire April 28, 2022

Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022

Business Wire April 8, 2022

Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022

Business Wire March 8, 2022

Xencor Reports Fourth Quarter and Full Year 2021 Financial Results

Business Wire February 23, 2022

Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022

Business Wire February 16, 2022

Xencor to Present at Upcoming Investor Conferences

Business Wire February 2, 2022

Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

Business Wire January 11, 2022

Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference

Business Wire January 6, 2022

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Business Wire December 12, 2021

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Business Wire November 21, 2021

Xencor to Present at Upcoming Investor Conferences

Business Wire November 19, 2021

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

Business Wire November 12, 2021

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting

Business Wire November 12, 2021

Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306

Business Wire November 8, 2021

Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting

Business Wire November 4, 2021

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS' Multidisciplinary NET Medical Virtual Symposium

Business Wire November 3, 2021

Xencor to Present at Upcoming Investor Conferences

Business Wire November 2, 2021

Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021

Business Wire November 1, 2021